Table 1.
Clinical characteristics of the cohort includes subjects who completed the SCOT trial per-protocol (PP) and for which gene expression was available at baseline
| Gene expression dataset—PP | |||
|---|---|---|---|
| Cyclophosphamide | Transplantation | ||
| Characteristic | n=33 | n=30 | P value |
| Age-mean (SD) | 46.1 (10.7) | 43.8 (10.1) | 0.379 |
| Female sex-no (%) | 23 (69.7) | 15 (50.0) | 0.129 |
| Race | |||
| White-no (%) | 25 (75.8) | 23 (76.7) | 0.805 |
| Black/African-American-no (%) | 4 (12.1) | 2 (6.7) | |
| Asian-no (%) | 1 (3.0) | 2 (6.7) | |
| Multiple-no (%) | 3 (9.1) | 2 (6.7) | |
| Other/unknown-no (%) | 0 (0.0) | 1 (3.3) | |
| Ethnicity Hispanic or Latino-no (%) | 4 (12.1) | 3 (10.0) | >0.999 |
| Smoking history | |||
| Current-no (%) | 2 (6.1) | 1 (3.3) | 0.410 |
| Ever-no (%) | 5 (15.2) | 9 (30.0) | |
| Never-no (%) | 26 (78.8) | 20 (66.7) | |
| Duration of disease-months since onset of first non-Raynaud’s Sign or symptom of scleroderma-mean (SD) | 30.8 (16.4) | 24.9 (12.8) | 0.117 |
| Disease-modifying antirheumatic drug use within 6 months of randomisation-no (%) | 21 (63.6) | 23 (76.7) | 0.287 |
| Lung involvement-no (%) | 32 (97.0) | 30 (100.0) | >0.999 |
| modified Rodnan Skin Score-mean (SD) | 30.4 (10.7) | 27.5 (7.7) | 0.225 |
| Mean FVC-% of predicted value | 73.6 (17.9) | 76.2 (13.4) | 0.525 |
| Mean DLCO-% of predicted value | 51.8 (7.9) | 54.1 (6.7) | 0.207 |
| Failures prior to month 54-no (%) | 16 (48.4) | 5 (16.7) | 0.0088 |
Fisher’s exact test was used for categorical variables and Student’s t-test was used for continuous measures.
DLCO, diffusing lung capacity for carbon monoxide; FVC, forced vital capacity; SCOT, Scleroderma: Cyclophosphamide or Transplantation.